Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium

Neurology

Volumn 65, Issue 12, 2005, Pages 1863-1872

  McKeith, I G ^a,al   Dickson, D W ^b   Lowe, J ^c   Emre, M ^d   O'Brien, J T ^a   Feldman, H ^e   Cummings, J ^f   Duda, J E ^g   Lippa, C ^h   Perry, E K ^a   Aarsland, D ⁱ   Arai, H ^j   Ballard, C G ^k   Boeve, B ^l   Burn, D J ^a   Costa, D ^m   Del Ser, T ⁿ   Dubois, B ^o   Galasko, D ^p   Gauthier, S ^r   Goetz, C G ^s   Gomez Tortosa, E ^t   Halliday, G ^u   Hansen, L A ^q   Hardy, J ^v   Iwatsubo, T ^w   Kalaria, R N ^a   Kaufer, D ^x   Kenny, R A ^a   Korczyn, A ^y   Kosaka, K ^z   Lee, V M Y ^aa   Lees, A ^ab   Litvan, I ^ac   Londos, E ^ad   Lopez, O L ^ae   Minoshima, S ^af   Mizuno, Y ^ag   Molina, J A ^ah   Mukaetova Ladinska, E B ^a   Pasquier, F ^ai   Perry, R H ^a   Schulz, J B ^aj   Trojanowski, J Q ^aa   Yamada, M ^ak   more..

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d ISTANBUL UNIVERSITY   (Turkey)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

ⁱ STAVANGER UNIVERSITY HOSPITAL   (Norway)

^j TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k KING'S COLLEGE LONDON   (United Kingdom)

^l MAYO CLINIC   (United States)

^m HPP Medicina Molecular SA   (Portugal)

ⁿ HOSPITAL SEVERO OCHOA   (Spain)

^o PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^p UNIVERSITY OF CALIFORNIA   (United States)

^q UNIVERSITY OF CALIFORNIA   (United States)

^r MCGILL UNIVERSITY   (Canada)

^s RUSH UNIVERSITY MEDICAL CENTER   (United States)

^t Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^u NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^v Gateway Building 3C309   (United States)

^w UNIVERSITY OF TOKYO   (Japan)

^x UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^y TEL AVIV UNIVERSITY   (Israel)

^z Fukushimera Hospital   (Japan)

^aa UNIVERSITY OF PENNSYLVANIA   (United States)

^ab UNIVERSITY COLLEGE LONDON   (United Kingdom)

^ac University of Louisville School of Medicine   (United States)

^ad LUND UNIVERSITY HOSPITAL   (Sweden)

^ae UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^af UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^ag JUNTENDO UNIVERSITY   (Japan)

^ah HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^ai Centre Hospitalier et Universitaire   (France)

^aj UNIVERSITY OF GÖTTINGEN   (Germany)

^ak KANAZAWA UNIVERSITY   (Japan)

^al NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLONAZEPAM; CLOZAPINE; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE TRANSPORTER; LEVODOPA; MELATONIN; NEUROLEPTIC AGENT; PLACEBO; QUETIAPINE; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AUTONOMIC DYSFUNCTION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DEMENTIA WITH LEWY BODY; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG SENSITIVITY; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; GENE ACTIVITY; HUMAN; HYPERSALIVATION; IMMUNOHISTOCHEMISTRY; LACRIMATION; LEWY BODY; MOTOR DYSFUNCTION; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROPATHOLOGY; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REM SLEEP; REVIEW; SIDE EFFECT; SLEEP DISORDER; THOUGHT DISORDER; URINARY FREQUENCY; VISUAL HALLUCINATION; BRAIN; CORPUS STRIATUM; DRUG TOLERANCE; METABOLISM; PARASOMNIA; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PRACTICE GUIDELINE;

ALPHA-SYNUCLEIN; BRAIN; CORPUS STRIATUM; DIAGNOSIS, DIFFERENTIAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DRUG TOLERANCE; HUMANS; LEWY BODIES; LEWY BODY DISEASE; REM SLEEP BEHAVIOR DISORDER;

EID: 33144489150     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000187889.17253.b1     Document Type: Review

References (105)

1. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
2. McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop. Neurology 1999;53:902-905.
3. McKeith I, Mintzer J, Aarsland D, et al. Dementia with Lewy bodies. Lancet Neurol 2004;3:19-28.
4. Litvan I, Bhatia KP, Burn DJ, et al. SIC Task Force Appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 2003;18:467-486.
5. Luis CA, Barker WW, Gajaraj K, et al. Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample. Int J Geriatr Psychiatry 1999;14:526-533.
6. Mega MS, Masterman DL, Benson F, et al. Dementia with Lewy bodies: reliability and validity of clinical and pathologic criteria. Neurology 1996;47:1403-1409.
7. Del Ser T, Hachinski V, Merskey H, Munoz DG. Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: effect of coexisting Alzheimer-type lesion load. Alzheimer Dis Assoc Disord 2001;15:31-44.
8. Merdes AR, Hansen LA, Jeste DV, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003;60:1586-1590.
9. Ballard CG, Jacoby R, Del Ser T, et al. Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with Lewy bodies. Am J Psychiatry 2004;161:843-849.
10. McKeith IG, Perry RH, Fairbairn AF, Jabeen S, Perry EK. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 1992;22:911-922.
11. Collerton D, Burn D, McKeith I, O'Brien J. Systematic review and meta-analysis show that dementia with Lewy bodies is a visualperceptual and attentional-executive dementia. Dement Geriatr Cogn Disord 2003;16:229-237.
12. Calderon J, Perry RJ, Erzinclioglu SW, Berrios GE, Dening TR, Hodges JR. Perception, attention, and working memory are disproportionately impaired in dementia with Lewy bodies compared with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;70:157-164.
13. Walker Z, Allan RL, Shergill S, Katona CLE. Neuropsychological performance in Lewy body dementia and Alzheimer's disease. Br J Psychiatry 1997;170:156-158.
14. Connor DJ, Salmon DP, Sandy TJ, Galasko D, Hansen LA, Thal LJ. Cognitive profiles of autopsy-confirmed Lewy body variant vs pure Alzheimer disease. Arch Neurol 1998;55:994-1000.
15. Mormont E, Grymonprez LL, Baisset-Mouly C, Pasquier F. The profile of memory disturbance in early Lewy body dementia differs from that in Alzheimer's disease. Rev Neurol. 2003; 159: 762-766.
16. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-392.
17. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003;2:229-237.
18. Molloy S, McKeith I, O'Brien JT, Burn D. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2005 76:1200-1203.
19. Bonelli SB, Ransmayr G, Steffelbauer M, Lukas T, Lampl C, Deibl M. L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology 2004;63:376-378.
20. Aarsland D, Litvan I, Salmon D, Galasko D, Wentzel-Larsen T, Larsen JP. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003;74:1215-1220.
21. Ballard CG, Aarsland D, McKeith IG, et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 2002;59:1714-1720.
22. Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 2001;16:528-536.
23. Boeve BF, Silber MH, Ferman TJ, et al. REM sleep behaviour disorder and degenerative dementia. An association likely reflecting Lewy body disease. Neurology 1998;51:363-370.
24. Wenning GK, Scherfler C, Granata R, et al. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry 1999;67:620-623.
25. Aarsland D, Ballard C, McKeith I, Perry RH, Larsen JP. Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001;13:374-379.
26. Aarsland D, Ballard C, Larsen JP, McKeith I, O'Brien J, Perry R. Marked neuroleptic sensitivity in dementia with Lewy bodies and Parkinson's disease. J Clin Psychiatry 2005;66:633-637.
27. McKeith I, Del-Ser T, Spano PF, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-2036.
28. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-2518.
29. Apaydin H, Ahlskog E, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology. Later-developing dementia and loss of levodopa response. Arch Neurol 2002;59:102-112.
30. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000;54:1916-1921.
31. Kovari E, Gold G, Giannakopoulos P, Lovero P, Surini M, Bouras C. Lewy body pathology in different neurodegenerative diseases. Brain Pathol 2000;10:518-519.
32. Cummings JL. Fluctuations in cognitive function in dementia with Lewy bodies. Lancet Neurol 2004;3:266.
33. Bradshaw JSM, Hopwood M, Anderson V, Brodtmann A. Fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease is qualitatively distinct. J Neurol Neurosurg Psychiatry 2004;75:382-387.
34. Ferman TJ, Smith GE, Boeve BF, et al. DLB fluctuations: specific features that reliably differentiate from AD and normal aging. Neurology 2004;62:181-187.
35. Walker MP, Ayre GA, Cummings JL, et al. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. Br J Psychiatry 2000;177:252-256.
36. Walker MP, Ayre GA, Cummings JL, et al. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease and vascular dementia. Neurology 2000;54:1616-1624.
37. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
38. Mosimann UP, Rowan EN, Partington CE, et al. Characteristics of visual hallucinations in Parkinson's disease dementia and dementia with Lewy bodies. Am J Geriatr Psychiatry (in press).
39. Mori E, Shimomura T, Fujimori M, et al. Visuoperceptual impairment in dementia with Lewy bodies. Arch Neurol 2000;57:489-493.
40. Mosimann UP, Mather G, Wesnes K, O'Brien J, Burn D, McKeith IG. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology 2004;63:2091-2096.
41. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002;125:391-403.
42. Lobotesis K, Fenwick JD, Phipps A, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 2001;56:643-649.
43. Colloby SJ, Fenwick JD, Williams ED, et al. A comparison of 99mTc-HMPAO SPECT changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping. Eur J Nucl Med 2002;29:615-622.
44. Higuchi M, Tashiro M, Arai H, et al. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol 2000;162:247-256.
45. Perry EK, McKeith I, Thompson P, et al. Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease and Alzheimer's disease. Ann NY Acad Sci 1991;640:197-202.
46. Ballard C, Piggott M, Johnson M, et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 2000;48:868-876.
47. McKeith IG, Wesnes KA, Perry E, Ferrara R. Hallucinations predict attentional improvements with rivastigmine in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2004;18:94-100.
48. Ballard C, O'Brien J, Swann A, et al. One year follow-up of parkinsonism in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2000;11:219-222.
49. Burn DJ, Rowan EN, Minett T, et al. Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: a cross-sectional comparative study. Mov Disord 2003;18:884-889.
50. Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent developments in Parkinson's disease. New York: McMillan, 1987;153-163.
51. Ballard C, McKeith I, Burn D, et al. The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies. Acta Neurol Scand 1997;96:366-371.
52. Duda JE, Giasson BI, Mabon ME, Lee VMY, Trojanowski JQ. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 2002;52:205-210.
53. Boeve BF, Silber MH, Ferman TJ. REM sleep behavior disorder in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004;17:146-157.
54. Boeve BF, Silber MH, Parisi JE, et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology 2003;61:40-45.
55. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992;305:673-678.
56. Swanberg MM, Cummings JL. Benefit-risk considerations in the treatment of dementia with Lewy bodies. Drug Safety 2002;25:511-523.
57. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 2003;18:1415-1423.
58. Piggott MA, Marshall EF, Thomas N, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 1999;122:1449-1468.
59. O'Brien JT, Colloby SJ, Fenwick J, et al. Dopamine transporter loss visualised with FP-CIT SPECT in dementia with Lewy bodies. Arch Neurol 2004;61:919-925.
60. Walker Z, Costa DC, Walker RWH, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002;73:134-140.
61. Horimoto Y, Matsumoto M, Akatsu H, et al. Autonomic dysfunctions in dementia with Lewy bodies. J Neurol 2003;250:530-533.
62. Kuzuhara S, Yoshimura M. Clinical and neuropathological aspects of diffuse Lewy body disease in the elderly. Adv Neurol 1993;60:464-469.
63. Del-Ser T, Munoz DG, Hachinski V. Temporal pattern of cognitive decline and incontinence is different in Alzheimer's disease and diffuse Lewy body disease. Neurology 1996;46:682-686.
64. Ballard C, Shaw F, McKeith I, Kenny RA. High prevalence of neurovascular instability in neurodegenerative dementias. Neurology 1998;51:1760-1762.
65. Birkett DP, Desouky A, Han L, Kaufman M. Lewy bodies in psychiatric patients. Int J Geriatr Psychiatry 1992;7:235-240.
66. Jellinger KA. Neuropathological spectrum of synucleinopathies. Mov Disord. 2003; 18(suppl 6): S2-12.
67. McKeith IG, Ballard CG, Perry RH, et al. Prospective validation of Consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000;54:1050-1058.
68. Galasko D. Biomarkers in non-Alzheimer dementias. Clin Neurosci Res 2004;3:375-381.
69. Barber R, Ballard C, McKeith IG, Gholkar A, O'Brien JT. MRI volumetric study of dementia with Lewy bodies. A comparison with AD and vascular dementia. Neurology 2000;54:1304-1309.
70. Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O'Brien JT. Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology 1999;52:1153-1158.
71. Cousins DA, Burton EJ, Burn D, Gholkar A, McKeith IG, O'Brien JT. Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer's disease: an MRI study. Neurology 2003;61:1191-1195.
72. Ishii K, Hosaka K, Mori T, Mori E. Comparison of FDG-PET and IMP-SPECT in patients with dementia with Lewy bodies. Ann Nucl Med 2004;18:447-451.
73. Albin RL, Minoshima S, Damato CJ, Frey KA, Kuhl DA, Sima AAF. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996;47:462-466.
74. Minoshima S, Foster NL, Sima AAF, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001;50:358-365.
75. Middelkoop HAM, van der Flier WM, Burton EJ, et al. Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. Neurology 2001;57:2117-2120.
76. Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O'Brien JT. MRI volumetric correlates of white matter lesions in dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 2000;15:911-916.
77. O'Brien JT, Paling S, Barber R, et al. Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology 2001;56:1386-1388.
78. Yoshita M, Taki J, Yamada M. A clinical role for I-123 MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2001;71:583-588.
79. Taki J, Yoshita M, Yamada M, Tonami N. Significance of I-123-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: It can be a specific marker for Lewy body disease. Ann Nucl Med 2004;18:453-461.
80. Kosaka K. Lewy bodies in cerebral cortex. Report of three cases. Acta Neuropathol 1978;42:127-134.
81. Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree - A new disease? Clin Neuropathol 1984;3:185-192.
82. Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 2000;10:378-384.
83. McNaught KS, Shashidharan P, Perl DP, Jenner P, Olanow CW. Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci 2002;16:2136-2148.
84. Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem 2004;279:4625-4631.
85. Lippa CF, McKeith I. Dementia with Lewy bodies: improving diagnostic criteria. Neurology 2003;60:1571-1572.
86. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) II. Standardisation of the neuropathological assessment of Alzheimer's disease. Neurology 1991;41:479-486.
87. NIA. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 1997;18(4 suppl):s1-2.
88. Lopez OL, Becher JT, Kaufer DI, et al. Research evaluation and prospective diagnosis of dementia with Lewy bodies. Arch Neurol 2002;59:43-46.
89. Harding AJ, Kril JJ, Halliday GM. Practical measures to simplify the Braak tangle staging method for routine pathological screening. Acta Neuropathol 2000;99:199-208.
90. Braak H, Del Tredici K, Rub U, de Vos RAI, Steur E, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
91. Lippa CF, Fujiwara H, Mann DM, et al. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 1998;153:1365-1370.
92. Popescu A, Lippa CF, Lee VMY, Trojanowski JQ. Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions. Arch Neurol 2004;61:1915-1919.
93. Tsuang DW, DiGiacomo L, Bird TD. Familial occurrence of dementia with Lewy bodies. Am J Geriatr Psychiatry 2004;12:179-188.
94. Gwinn-Hardy K, Singleton AA. Familial Lewy body diseases. J Geriatr Psychiatry Neurol 2002;15:217-223.
95. Trembath Y, Rosenberg C, Ervin JF, et al. Lewy body pathology is a frequent co-pathology in familial Alzheimer's disease. Acta Neuropathol 2003;105:484-488.
96. Singleton A, Gwinn-Hardy K. Parkinson's disease and dementia with Lewy bodies: a difference in dose? Lancet 2004;364:1105-1107.
97. Johnson J, Hague SM, Hanson M, et al. SNCA multiplication is not a common cause of Parkinson disease or dementia with Lewy bodies. Neurology 2004;63:554-556.
98. Barber R, Panikkar A, McKeith IG. Dementia with Lewy bodies: diagnosis and management. Int J Geriatr Psychiatry 2001;16:S12-S18.
99. Fernandez HH, Wu CK, Ott BR. Pharmacotherapy of dementia with Lewy bodies. Exp Opin Pharmacother 2003;4:2027-2037.
100. Terao T, Shimomura T, Izumi Y, Nakamura J. Two cases of quetiapine augmentation for donepezil-refractory visual hallucinations in dementia with Lewy bodies. J Clin Psychiatry 2003;64:1520-1521.
101. Burke WJ, Pfeiffer RF, McComb RD. Neuroleptic sensitivity to clozapine in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci 1998;10:227-229.
102. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment. Mov Disord 2001;16:1171-1174.
103. Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004;17:164-171.
104. Samuel W, Caligiuri M, Galasko D, et al. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 2000;15:794-802.
105. Grace J, Daniel S, Stevens T, et al. Long-term use of rivastigmine in patients with dementia with Lewy bodies: An open-label trial. Int Psychogeriatr 2001; 13: 199-205.